journal article·2018-07-25

Polyamino Acid Layer-by-Layer (LbL) Constructed Silica-Supported Mesoporous Titania Nanocarriers for Stimuli-Responsive Delivery of microRNA 708 and Paclitaxel for Combined Chemotherapy

Biki Gupta, Hima Bindu Ruttala, Bijay Kumar Poudel, Shiva Pathak, Shobha Regmi, Milan Gautam, Kishwor Poudel, Min Hyun Sung, Wenquan Ou, Sung Giu Jin, Jee-Heon Jeong, Sae Kwang Ku, Han-Gon Choi, Chul Soon Yong, Jong Oh Kim

ACS Applied Materials & Interfaces· Volume 10· Issue 29
Publisher page

Abstract

Cellular Fas-associated protein with death domain-like interleukin-1β-converting enzyme-inhibitory protein (c-FLIP), often strongly expressed in numerous cancers, plays a pivotal role in thwarting apoptosis and inducing chemotherapy resistance in cancer. An integrated approach combining chemotherapy with suppression of c-FLIP levels could prove paramount in the treatment of cancers with c-FLIP overexpression. In this study, we utilized a polymeric layer-by-layer (LbL) assembly of silica-supported mesoporous titania nanoparticles (MTNst) to co-deliver paclitaxel (PTX) and microRNA 708 (miR708) for simultaneous chemotherapy and c-FLIP suppression in colorectal carcinoma. The resulting LbL miR708/PTX-MTNst showed dose-dependent cytotoxicity in HCT-116 and DLD-1 colorectal carcinoma cell lines, which was remarkably superior to that of free PTX or LbL PTX-MTNst. LbL miR708/PTX-MTNst strongly inhibited c-FLIP expression and resulted in increased expression of proapoptotic proteins. In DLD-1 xenograft tumor-bearing mice, the nanoparticles accumulated in the tumor, resulting in remarkable tumor regression, with the PTX and miR708-loaded nanoparticles showing significantly greater inhibitory effects than the free PTX or PTX-loaded nanoparticles. Immunohistochemical analyses of the tumors further confirmed the remarkable apoptotic and antiproliferative effects of the nanoparticles, whereas organ histology reinforced the biocompatibility of the system. Therefore, the LbL miR708/PTX-MTNst system, owing to its ability to deliver both chemotherapeutic drug and inhibitory miRNA to the tumor site, shows great potential to treat colorectal carcinoma in clinical settings.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: RNA Interference and Gene Delivery · Advanced biosensing and bioanalysis techniques · Nanoparticle-Based Drug Delivery

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

College of Pharmacy, Yeungnam University, 214-1, Dae-Dong, Gyeongsan 712-749, Republic of Korea

Department of Pharmaceutical Engineering, Dankook University, 119 Dandae-ro, Dongnam-gu, Cheonan 31116, Republic of Korea

College of Korean Medicine, Daegu Haany University, Gyeongsan 712-702, Republic of Korea

College of Pharmacy, Institute of Pharmaceutical Science and Technology, Hanyang University, 55, Hanyangdaehak-ro, Sangnok-gu, Ansan 426-791, Republic of Korea

Funding

National Research Foundation of Korea

References (71)

Show source-provided references
1. Safa A. R. · Exp. Oncol. · 2012 · 34 · 176
2. 10.4172/2157-2518.S6-00310.4172/2157-2518.S6-003 ↗
3. 10.1158/1078-0432.CCR-06-254710.1158/1078-0432.CCR-06-2547 ↗
4. 10.1016/j.ygyno.2007.01.05110.1016/j.ygyno.2007.01.051 ↗
5. 10.1186/1756-9966-28-2410.1186/1756-9966-28-24 ↗
6. 10.1002/ijc.1123910.1002/ijc.11239 ↗
7. 10.1111/j.1349-7006.2003.tb01402.x10.1111/j.1349-7006.2003.tb01402.x ↗
8. 10.1136/gut.2009.20232510.1136/gut.2009.202325 ↗
9. 10.1158/1078-0432.CCR-11-327710.1158/1078-0432.CCR-11-3277 ↗
10. 10.1210/en.2001-21102410.1210/en.2001-211024 ↗
11. 10.1038/sj.onc.120912210.1038/sj.onc.1209122 ↗
12. 10.1016/j.bcp.2006.02.01510.1016/j.bcp.2006.02.015 ↗
13. 10.1158/0008-5472.CAN-06-358510.1158/0008-5472.CAN-06-3585 ↗
14. 10.1016/j.bcp.2006.02.01510.1016/j.bcp.2006.02.015 ↗
15. 10.3892/or_0000078410.3892/or_00000784 ↗
16. 10.18632/oncotarget.714910.18632/oncotarget.7149 ↗
17. 10.1016/j.addr.2014.05.00910.1016/j.addr.2014.05.009 ↗
18. 10.1002/anie.20120807710.1002/anie.201208077 ↗
19. 10.1158/1535-7163.MCT-14-020910.1158/1535-7163.MCT-14-0209 ↗
20. 10.1016/j.jconrel.2015.04.00210.1016/j.jconrel.2015.04.002 ↗
21. 10.1016/j.jconrel.2014.11.01010.1016/j.jconrel.2014.11.010 ↗
22. 10.1016/j.jconrel.2012.01.01410.1016/j.jconrel.2012.01.014 ↗
23. 10.1016/j.biomaterials.2014.02.00610.1016/j.biomaterials.2014.02.006 ↗
24. 10.1016/j.biomaterials.2013.11.03910.1016/j.biomaterials.2013.11.039 ↗
25. 10.1021/nn507465d10.1021/nn507465d ↗
26. 10.1371/journal.pone.003812910.1371/journal.pone.0038129 ↗
27. 10.1002/anie.20130892010.1002/anie.201308920 ↗
28. Olariu C. I. · 2010
29. 10.1039/c3tb20455c10.1039/c3tb20455c ↗
30. 10.1021/jacs.5b0117210.1021/jacs.5b01172 ↗
31. 10.1016/j.jconrel.2017.04.04310.1016/j.jconrel.2017.04.043 ↗
32. 10.1016/j.elecom.2006.03.03710.1016/j.elecom.2006.03.037 ↗
33. 10.1016/j.solmat.2006.06.02110.1016/j.solmat.2006.06.021 ↗
34. 10.1021/ac902105510.1021/ac9021055 ↗
35. 10.1016/j.electacta.2011.10.01710.1016/j.electacta.2011.10.017 ↗
36. 10.1002/chem.20130073710.1002/chem.201300737 ↗
37. 10.1016/j.bios.2013.08.05410.1016/j.bios.2013.08.054 ↗
38. 10.1021/ac502876u10.1021/ac502876u ↗
39. 10.1016/j.cej.2016.01.00810.1016/j.cej.2016.01.008 ↗
40. 10.1039/C6TA09890H10.1039/C6TA09890H ↗
41. 10.1039/C5RA15120A10.1039/C5RA15120A ↗
42. 10.1021/acsami.7b0315510.1021/acsami.7b03155 ↗
43. 10.1039/c1cc10659g10.1039/c1cc10659g ↗
44. 10.1039/c1jm10407a10.1039/c1jm10407a ↗
45. 10.1021/ja058083c10.1021/ja058083c ↗
46. 10.1002/chem.20110357110.1002/chem.201103571 ↗
47. 10.1039/C4TA06891B10.1039/C4TA06891B ↗
48. 10.1039/C5NR05692F10.1039/C5NR05692F ↗
49. 10.1016/j.conbuildmat.2017.06.05410.1016/j.conbuildmat.2017.06.054 ↗
50. 10.1016/j.jcis.2017.06.06310.1016/j.jcis.2017.06.063 ↗
51. 10.1039/b918590a10.1039/b918590a ↗
52. 10.1186/s11671-016-1585-410.1186/s11671-016-1585-4 ↗
53. 10.1021/cm503304p10.1021/cm503304p ↗
54. 10.1016/j.carbpol.2016.03.03710.1016/j.carbpol.2016.03.037 ↗
55. 10.1016/j.actbio.2014.08.02110.1016/j.actbio.2014.08.021 ↗
56. 10.1016/j.carbpol.2013.11.00910.1016/j.carbpol.2013.11.009 ↗
57. 10.1016/j.ijpharm.2017.01.01110.1016/j.ijpharm.2017.01.011 ↗
58. 10.1016/0021-9797(68)90272-510.1016/0021-9797(68)90272-5 ↗
59. 10.1002/adfm.20130025510.1002/adfm.201300255 ↗
60. 10.1021/nn203964310.1021/nn2039643 ↗
61. 10.1007/s11095-017-2337-610.1007/s11095-017-2337-6 ↗
62. 10.1016/j.colsurfb.2018.02.01510.1016/j.colsurfb.2018.02.015 ↗
63. 10.1007/s40005-014-0152-110.1007/s40005-014-0152-1 ↗
64. 10.1021/acsami.6b0916310.1021/acsami.6b09163 ↗
65. 10.1039/C4NR04864D10.1039/C4NR04864D ↗
66. 10.1021/am100188q10.1021/am100188q ↗
67. 10.1007/s11095-015-1673-710.1007/s11095-015-1673-7 ↗
68. 10.1208/s12249-015-0384-z10.1208/s12249-015-0384-z ↗
69. 10.1021/js960522610.1021/js9605226 ↗
70. 10.2147/IJN.S8958410.2147/IJN.S89584 ↗
71. 10.1038/nrm315110.1038/nrm3151 ↗